Cardima completes atrial fibrillation study:
This article was originally published in Clinica
Cardima, a US developer of microcatheter systems for diagnosing and treating abnormal heart rhythms, has completed a feasibility study of a device for treating atrial fibrillation. The ten-patient study took place at three US hospitals and the Fremont, California-based company plans to submit the results to the FDA by the end of the year to expand the trial to ten US centres. The device is already CE-marked in Europe.
You may also be interested in...
AdvaMed Accell executive director Ashley Wittorf spoke in support of a proposed US House bill that would give financial help to small companies making products to address COVID-19.
Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma.
A pilot that used RFID tags with 2D barcodes was touted as more effective than using 2D barcodes alone in tracking drugs through the supply chain.